MedTrace Logo

Screening for Ovarian Malignancy

NCT06348784 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-04-05

No results posted yet for this study

Summary

Ovarian cancer is the second most common gynecologic malignancy. In 2008, it was the seventh leading cause of cancer deaths in women worldwide. Estimating the risk of malignancy is essential in the management of adnexal masses and several mathematical models and scoring systems have been developed to be used for discrimination between benign and malignant adnexal masses. Knowledge of the specific type of adnexal pathology before surgery is likely to improve patient triage with high accuracy, and it also makes it possible to optimize treatment. The correct identification of stage I cancer is particularly important

Conditions

  • Early Detection of Ovarian Cancer

Interventions

DIAGNOSTIC_TEST

Assesment of Different NEoplasias in the adenexa model

The ADNEX model includes nine parameters; Age, CA-125 level, Oncology center (yes/no), and 6 ultrasound features which are maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules (yes/no), number of papillary projections (0/1/2/3/more than 3), acoustic shadow, and ascites

DIAGNOSTIC_TEST

Risk of malignancy index

The RMI was measured as follows; Menopausal status (score is 3 as all patients were postmenopausal X Ultrasound score is based on assessment of 5 features and with the presence of one feature, the score is 1 while if more than one feature is present, the score is 3; the five ultrasound features are the presence of solid components, multilocularity, bilaterality, ascites, and metastases X CA - 125 level

DIAGNOSTIC_TEST

Histopathologic examination

Histopathologic examination of all excised specimens was done as this is the gold standard test for detecting ovarian malignancy

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Principal Investigators

  • Amr H El-Shalakany, M.D. · Ain Shams University

  • Kareem M Labib, M.D. · Ain Shams University

  • Hassan Morsi, PhD · Ain Shams University

  • Mortada Elsayed, M.D. · Ain Shams University

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06348784 on ClinicalTrials.gov